India, April 23 -- Tuesday, BeiGene, Ltd. (BGNE) announced the European Commission's or EC approval of Tislelizumab for treating non-small cell lung cancer in three specific scenarios.
The company said the approval of Tislelizumab could be in combination with carboplatin and either paclitaxel or nab-paclitaxel for treating adult patients with squamous non-small cell lung cancer in the first-line setting.
Further, it could be combined with pemetrexed and platinum-based chemotherapy for treating adult patients with non-squamous non-small cell lung cancer in the first-line setting. EC also approved Tislelizumab alone for treating adult patients with locally advanced or metastatic non-small cell lung post-prior platinum-based therapy.
The EC...